Abstract
Allogeneic natural killer (NK) cell-based immunotherapy is a promising, well-tolerated adjuvant therapeutic approach for acute myeloid leukemia (AML). For reproducible NK cell immunotherapy, a homogenous, pure and scalable NK cell product is preferred. Therefore, we developed a good manufacturing practice (GMP)-compliant, cytokine-based ex vivo manufacturing process for generating NK cells from CD34+ hematopoietic stem and progenitor cells (HSPC). This manufacturing process combines amongst others IL15 and IL12 and the aryl hydrocarbon receptor antagonist StemRegenin-1 (SR1) to generate a consistent and active NK cell product that fits the requirements for NK cell immunotherapy well. The cell culture protocol was first optimized to generate NK cells with required expansion and differentiation capacity in GMP-compliant closed system cell culture bags. In addition, phenotype, antitumor potency, proliferative and metabolic capacity were evaluated to characterize the HSPC-NK product. Subsequently, seven batches were manufactured for qualification of the process. All seven runs demonstrated consistent results for proliferation, differentiation and antitumor potency, and preliminary specifications for the investigational medicinal product for early clinical phase trials were set. This GMP-compliant manufacturing process for HSPC-NK cells (named RNK001 cells) is used to produce NK cell batches applied in the clinical trial ‘Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL2 in patients with acute myeloid leukemia’ approved by the Dutch Ethics Committee (EudraCT 2019-001929-27).
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and incidence increases with age [1]. Treatment with intensive chemotherapy and/or hypomethylating agents (HMA) combined with venetoclax can result in complete remission (CR), often followed by consolidation with allogeneic stem cell transplantation (allo-SCT). Nevertheless, prognosis remains poor due to high relapse rates. Currently, 35–40% of younger and 5–15% of older AML patients are alive 5 years after diagnosis. Relapse occurs in 20–80% of patients, depending on the genomic risk classification and response to induction chemotherapy. Furthermore, persistent minimal residual disease (MRD) prior to allo-SCT has been associated with increased relapse rates and decreased survival [2]. Therefore, novel adjuvant therapies are needed to induce deeper remission before allo-SCT.
Allogeneic natural killer (NK) cell-based immunotherapy is a promising, non-toxic adjuvant therapeutic approach for AML. Various studies have shown that allogeneic NK cell infusion following lymphodepleting conditioning is well-tolerated and exerts anti-leukemia activity, achieving CR in up to 47% of the patients [3,4,5,6,7]. Generally, allogeneic NK cell products are enriched from peripheral blood (PB) of haplo-identical donors followed by overnight activation with Interleukin (IL)2, IL15 or the combination of IL12/IL15/IL18 [4, 5, 7,8,9,10]. However, because PB-NK cells have limited expansion capacity in vitro, have limited life spans in vivo, and represent a small fraction of peripheral white blood cells, obtaining sufficient cell numbers without T cell contamination is a major obstacle for adoptive transfer [3, 5, 11, 12]. Contaminating alloreactive T cells harbor the risk of graft-versus-host disease (GvHD) induction, especially when IL2 or IL15 is co-administered in vivo to boost NK cell survival, proliferation and activity. To increase NK cell numbers, so called feeder cell lines have been designed, like irradiated target cell line K562, genetically modified to express membrane-bound IL15 or IL21, resulting in > 10.000-fold expansion of PB-NK cells in 5 weeks [13, 14]. Although, the first clinical trials show safety, clinical efficacy can be further improved [15, 16]. In addition, PB-enriched cell products contain high donor-intervariability [3, 12].Therefore, preferable for adoptive immunotherapy is the development of homogeneous and scalable allogeneic NK cell products.
Autologous NK-cell products have shown not to be capable of achieving a potent anti-tumor response, possibly due to the interaction with MHC-class I molecules [17, 18]. Moreover, the expansion efficiency and functional status of autologous NK cells were limited when compared to allogeneic NK cells, as autologous cells were often obtained from heavily pretreated patients [12]. Next, NK cell lines such as NK-92 have been studied in several clinical trials. While large numbers could be generated and clinical responses were observed, there is a need for irradiation of the product to prevent uncontrolled proliferation after infusion. This limits the immunotherapeutic potential of cell lines as in vivo expansion is correlated to treatment outcome [5].
Alternatively, NK cells can be generated ex vivo from hematopoietic stem and progenitor cells (HSPC) or induced pluripotent stem cells (iPSC) [19]. Previously, we reported good manufacturing practice (GMP) manufacturing and clinical results from a phase I trial using NK cells derived from umbilical cord blood (UCB)-derived CD34+ HSPC using heparin-based culture media and amongst others IL2 and IL15 [20,21,22,23]. We demonstrated that infusion of up to 30 × 106/kg of these cells is feasible, safe and well-tolerated in older AML patients, who were ineligible for allo-SCT [21]. Recently, we revised the culture protocol by including the aryl hydrocarbon receptor (AhR) antagonist StemRegenin-1 (SR1), which enhances expansion of CD34+ HSPCs and upregulates NK-cell-specific transcription factors, and combining IL15 with low-dose IL12, which resulted in more robust expansion, strong potency, and higher maturation potential in vivo compared to previous IL2 based methods [24, 25]. In addition, these SR1/IL15/IL12-induced HSPC-NK cells have shown high cytotoxicity against AML cell lines and primary AML cells in vitro [24, 26, 27]. Here, we present data of pre-clinical process development and the qualification of our GMP-compliant manufacturing process for SR1/IL15/IL12 induced HSPC-NK cells (named RNK001 cells). Next, we describe our phase I/IIa clinical trial protocol to investigate the safety and efficacy of RNK001 cells in patients with AML or myelodysplastic syndrome with excess blasts (MDS-EB2) with residual disease, with and without in vivo IL2 cytokine support (EudraCT 2019-001929-27).
Materials and methods
HSPC-NK cell generation
HSPC-NK cells were generated from UCB-derived CD34+ progenitor cells. UCB units were derived from the Radboudumc cord blood bank (banked after written informed consent) or collected at caesarean sections using CB-collect bags (Fresenius Kabi) after written informed consent (approved by the Radboudumc Committee for Medical Research Ethics CMO 2014/226). When units from the Radboudumc cord blood bank were used, cryopreserved UCB units were thawed and CD34+ cells were magnetically isolated using the CliniMACS plus (Miltenyi Biotec). When collected at caesarean sections, CD34+ cells were magnetically isolated and cryopreserved from the mononuclear cells using a CD34 microbead kit (cat# 130-046-702, Miltenyi Biotec) after Ficoll-Paque separation within 24 h.
Isolated CD34+ cells were either cultured in CellGro Dendritic Cell (DC) specific medium (CellGenix) or NK MACS medium (Miltenyi Biotec) containing 2 or 10% Human serum (HS; Sanquin Bloodbank, Amsterdam, The Netherlands) and a specific mix of TPO (25 ng/ml, Immunotools, 500 U/ml, Miltenyi Biotec), FLT3L (25 ng/ml, Immunotools, 25 U/ml, Miltenyi Biotec), SCF (25 ng/ml, Immunotools, 25 U/ml, Miltenyi Biotec), IL7 (25 ng/ml, Immunotools, 2000 U/ml, Miltenyi Biotec), IL15 (50 ng/ml, Immunotools, 1000 U/ml, Miltenyi Biotec), IL12 (0.2 ng/ml, Immunotools, 0.25 U/ml, R&D systems) and/or SR1 (5 µM, Ardena) according to Fig. 1A (cytokines in ng/ml (Immunotools) for pre-validation and U/ml (Miltenyi Biotec and R&D systems) for GMP validation). 2% HS was used in differentiation medium for all cultures, except NK6 and NK7 in which 10% was used. Cells were cultured in 24 or 6-well plates (Corning) or VueLife 118/290/750 AC cell culture bags (Saint-Gobain). Cell concentration was maintained at around 2 million/ml by diluting the culture volume 1:3, 1:4 or 1:5 with fresh culture medium based on Trypan Blue Exclusion cell counting for both pre-validation and GMP validation. Medium volumes were based on calculated volumes per well/bag and was not measured. Cells were split when adding medium would result in > 5 ml in the 6-well culture or transferred from one 118 AC culture bag to two 750 AC culture bags at day 7 of the GMP validation. Cells were harvested and washed twice using CliniMACS PBS/EDTA buffer (Miltenyi Biotec) containing 0.5% Human Serum Albumin (HSA, Prothya Biosolutions). Finally, 1.0–3.0 × 109 RNK001 cells were formulated in 500 ml 0.9% NaCl (Baxter) containing 5% HSA (Prothya Biosolutions). Validation runs NK1–NK7 were performed according to GMP-compliant manufacturing protocol.
Tumor cell lines
K562 (RRID:CVCL_0004) were obtained from ATCC and cultured in Iscove’s Modified Dulbecco’s medium (IMDM; Gibco, #12440061) containing 10% FCS. Cell lines were cultured up to three months. Every 6 months, all cells in culture at that time were tested for mycoplasma with MycoAlertTM Mycoplasma Detection Kit (Lonza, #LT07-418).
Purity and yield
For the CellGro vs NK MACS comparison, NK cell purity was determined by staining with CD45-ECD (Beckman Coulter, #A07784) and CD56-PECy7 (Biolegend, # 318318) at 4 °C for 30 min and 7-AAD (1:1000 diluted, Sigma, #A9400) was added before acquiring the cells on the FC500 flowcytometer (Beckman Coulter). Data was analyzed using Kaluza V2.1.3. For validation runs, NK cell purity and absolute cell count was performed by the Radboudumc Laboratory for Hematology Immunophenotyping unit (ISO15189 certified). Total nucleated cell yield and fold expansion was based on trypan blue exclusion counting before cell harvesting.
Phenotyping
HSPC-NK cell phenotype was determined by staining for CD56-PE-Cy7 (Biolegend, #318318), NKG2A-APC (Beckman Coulter, #A60797), CD16-FITC (Biolegend, #302006), pan-KIRs-PE (Biolegend, #339506, 312606 and 312708), DNAM-1-FITC (BD, #559788), NKp46-PE (Biolegend, #331908) and NKG2D-APC (Biolegend, #320808) (CellGro vs NK MACS) or CD56-BV510 (Biolegend, #318340), CD45-BV421 (Biolegend, #368522), NKG2A-PE-Cy7 (Beckman Coulter, #B10246), DNAM-1-FITC (Biolegend, #337104), NKp46-PE (Biolegend, #311908), NKp44-PE (Biolegend, #325108), NKp30-APC (Biolegend, #325210) and NKG2D-APC (Biolegend, #320808) (GMP validations runs). Briefly, 200.000 cells were washed using PBS/0.5% BSA and incubated with antibodies in PBS/0.5% BSA at 4 °C for 30 min. Cells were then washed twice with PBS/0.5% BSA and resuspended in PBS/0.5% BSA containing Sytox Blue (1:5000 diluted, invitrogen, #S34857) for CellGro vs NK MACS experiments or 7-AAD (1:1000 diluted, Sigma, #A9400) for GMP validation runs. Cells were acquired on the Gallios (CellGro vs NK MACS) or Navios (GMP validation runs) flowcytometers and analyzed using Kaluza V2.1.3.
RNK001 potency
RNK001 potency was determined by challenging them with K562 cells. Briefly, 150.000 RNK001 cells were co-cultured with 100.000 K562 cells in the presence of CD107a-PECy7 (Biolegend, #328618) at 37 °C for 4 h. After 1 h, Brefeldin A (BD Bioscience, #5550229) was added. Next, cells were harvested and stained with CD56-BV510 (Biolegend, # 318340) and eFluor780 (eBiosciences, #65-0865-14) at 4 °C for 30 min. Cells were then fixed and permeabilized using eBiosciences Fix/Perm buffer (#00-5123-43, #005223-56 and #00-8333-56). Finally, cells were stained intracellularly for IFN-γ-FITC (BD bioscience, #554700) and Perforin-PE (Biolegend, #308106), washed, acquired on the Gallios flowcytometer (Beckmann Coulter) and analyzed using Kaluza V2.1.3.
Microbiology
RNK001 cells were tested according to European Pharmacopoeia (Ph. Eur.) 2.6.1 (sterility) and 2.6.14 (endotoxins) by Eurofins Bactimm. As the product is infused freshly, no sterility or endotoxin data is available at the time of infusion. Therefore, an in-process sterility and endotoxin test is performed at day 14/15 of the culture which is used for initial release. Pooled human serum is tested according to Ph. Eur. 2.6.7 (mycoplasma) by Eurfins MicroSafe Laboratories.
NK cell proliferation assay
After RNK001 generation, cells were rested in NK MACS/2% HS + 5 ng/ml rhIL15 (Immunotools). Eight days after resting, NK cells were labeled with eFluor450 (eBioScience, #65-0842-85) and cultured in RPMI + 10% HS with 12.8 ng/ml rhIL15 or 1000 U/ml rhIL2 (Chiron Corporation) or without cytokines. Medium was refreshed on day 3 and analysis was performed on day 6. Dead cells were excluded using 7-AAD. Proliferation gate was set on 1% in the no cytokine control. NK cell numbers were based on CD56 gating events (CD56− PE-Cy7, Beckman Coulter, #A21692) and measuring for a fixed time.
Metabolic assays
The XF96 Extracellular Flux Analyzer (Seahorse, Agilent) was used to measure extracellular acidification rates (ECAR) and oxygen consumption rates (OCR). The Glycolytic stress (GST) tests were performed in DMEM (cat#D5030, Sigma) containing 143 mM NaCl (cat#3624-01, Baker) and 3 ml/l Phenol Red (cat#P0290, Sigma), supplemented with 2 mM l-glutamine (cat#35050-061, Life Technologies). For mitochondrial stress tests (MST), 25 mM d-glucose (cat#4912-12, VWR) and 1 mM sodium pyruvate (cat#360-070, Life Technologies) was added to the GST medium. GST was measured in response to 80 mM d-glucose, 18 µM oligomycin (cat#75351, Sigma) and 1 M 2-deoxy-d-glucose (2DG, cat#D6134, Sigma). MST was measured in response to 16 µM oligomycin, 4.5 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP, cat#C2920, Sigma), 10 µM rotenone (cat#R8875, Sigma) and 10 µM antimycin A (cat#A8674, Sigma). PB-NK control cells were isolated from a buffy coat (Sanquin Blood Bank, Nijmegen, The Netherlands) using a CD56 microbead kit (cat# 130-050-401, Miltenyi Biotec) after Ficoll-Paque separation. Isolated CD56+ cells were rested for 7 days in RPMI-1640 containing 10% HS and 1 ng/ml IL15 (Immunotools). Half of the medium was replaced every other day.
Mass cytometry
HSPC-NK SR1/15.12 (according to Fig. 1A) and HSPC-NK Hep/15.2 (according to [21]) differentiated cells were thawed and stained as previously described with the NK panel (panel according to [7, 8]). Briefly, dead cells were stained using cisplatin, then cell surface antigens were stained. Thereafter cells were fixed and permeabilized using eBiosciences Fix/Perm buffer, according to manufacturer’s instructions. Intracellular markers were stained in eBiosciences Perm Wash buffer. After staining, cells were then barcoded using Fluidigm 20-plex Pd Barcoding kit, according to manufacturer’s instructions. Cells were then collected on a Helios mass cytometer (Fluidigm) and analyzed using Cytobank ([28]). Live Cells were debarcoded ([29]), and CD45+CD19−CD14−CD3−CD56+NKp46+ cells identified by traditional gating. NKp46+ NK Hep/15.2, and NK SR1/15.12 cells were assessed using viSNE ([30]). Subsets within tSNE1/2 were identified using FlowSOM (clustering: tSNE1/2, 5 metaclusters, 25 clusters; [31]).
Statistics
Statistical analysis was performed using Graphpad Prism software version 9.4.0. Two-tailed unpaired T-test, two-tailed Mann–Whitney test, Wilcoxon matched-pairs signed rank test, or two-way ANOVA were used as indicated in the figure legends. Significance was defined as p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****).
Results
HSPC-NK cell generation using NK MACS medium results in high proliferation and differentiation
We established a culture method to generate CD34+ progenitor-derived NK cells in the presence of the AhR antagonist SR1, IL15 and IL12 (Fig. 1A, [26]). To optimize the manufacturing process we changed the open 6-well culture system to a closed system using bags. Cell culture using CellGro DC medium in culture bags resulted in comparable proliferation compared to culture plates [median fold expansion in plates 443 times vs 322 times in bags (range 369–624 vs 237–431), non-significant (ns)]. However, it significantly delayed differentiation into CD56+ cells (median in plates at day 35 72% vs 25% in bags, range 66–76% vs 25–46%, p = 0.007) (Fig. 1B, C). Therefore, further optimization of the culture protocol was initiated by exploring HSPC-NK cell culture in 6-well plates for 35 days in NK specific NK MACS medium. This resulted in significantly increased proliferation (median fold expansion in CellGro DC medium 443 times vs 3810 times in NK MACS medium, range 369–624 vs 1879–4450, p = 0.02), as well as differentiation (median CD56+ NK cells in CellGro DC medium 72% vs 96% in NK MACS medium, range 66–76% vs 95–97%, p = 0.001) (Fig. 1D–E). Subsequently, these results were validated in closed system culture bags. Although cell expansion was lower in culture bags compared to 6-well plates (median fold increase in plates 3810 times vs 1654 times in bags, range 1879–4450 vs 426–2918, Fig. 1F, ns), final yield was 5 times higher for NK MACS medium compared to CellGro DC medium. This ensures a minimal desired dose of at least 1.0 × 109 CD56+ NK cells for our phase I/IIa trial (EudraCT 2019-001929-27). A minimum of 1.0 × 109 translates to ≥ 10 × 106 NK cells/kg for patients up to 100 kg body weight, which has shown to be both safe and sufficient to accomplish a clinical effect [3, 5, 21]. Importantly, cell differentiation was well above 70% CD56+CD3− expression (range 95–97% in plates vs 89–94% in bags, p = 0.04, Fig. 1G). This was a significant improvement compared to CellGro DC medium in culture bags (p < 0.001), where an average of only 32% could be achieved. These data demonstrate that high numbers of CD56+CD3− HSPC-NK cells can be generated with our optimized SR1/IL15/IL12 protocol using NK MACS medium and cell culture bags.
HSPC-NK cell generation using NK MACS medium results in functional NK cells with an active phenotype
To evaluate the functionality of the HSPC-NK cells generated using the NK MACS based protocol, we determined phenotype, potency, proliferation capacity and metabolic activity for independent cultures in 6-well plates. At the end of the culture the HSPC-NK cells expressed high levels of NKG2A, NKG2D, DNAM-1 and NKp46 (mean all ≥ 70%, mean ± SD: CD16 3.0% ± 2.4, NKG2A 85.8% ± 19.5, NKG2D 73.0% ± 21.3, KIRs 33.1% ± 11.8, DNAM-1 73.0% ± 20.6, Perforin 65.2% ± 10.5, NKp46 91.5% ± 12.9) (Fig. 1H). Moreover, functionality was evaluated after K562 challenge. 61.6% ± 4.5 of the CD56+perforin+ NK cells expressed degranulation marker CD107a and 10.7% ± 3.9 simultaneously produced IFNγ, which is comparable with NK cells generated in CellGro DC medium (Fig. 1I and Suppl Fig. 1, versus 8.3 ± 2.5 and 0.3 ± 0.2 respectively for unstimulated CD56+perforin+ NK cells, mean ± SEM) [26]. In addition, high proliferative capacity of 85.1% ± 1.0 for IL2 and 95.1% ± 0.1 for IL15 activated NK cells was shown (Fig. 1J). Finally, HSPC-NK cells were evaluated in glycolytic and mitochondrial stress tests, in comparison to PB-NK cells (Fig. 1K–L). Next, fold increase of the two donors per NK cell source, measured in duplo or triplo, were pooled. The changes in ECAR and OCR were analyzed showing comparable glycolysis [HSPC-NK 1.4 ± 0.4 fold change (mean ± SEM) vs PB-NK 0.8 ± 0.1], glycolytic capacity (HSPC-NK 4.3 ± 1.4 fold change vs PB-NK 3.9 ± 0.9), and maximal respiration (HSPC-NK 4.7 ± 0.7 fold change vs PB-NK 3.3 ± 0.2). All together these data show that the NK MACS based protocol results in robust proliferation and differentiation towards potent, functional and metabolically active CD56+ NK cells.
Successful validation of the RNK001 manufacturing process
For validation of the manufacturing process seven independent runs were performed, using different UCB units, to establish the reproducibility of the culture process as documented in our investigational medicinal product dossier (Table 1). All cultures showed similar expansion patterns (Fig. 2A). Total number of nucleated cells ranged between 2.4 × 109 and 4.5 × 109 cells (670–2076 fold expansion) before harvesting the cells (Fig. 2A, B). The percentage of CD45+CD56+CD3− cells ranged between 70 and 96%, with a mean of 84%, resulting in an absolute NK cell number of 1.0 × 109 to 2.9 × 109, with a mean of 2.1 × 109, after harvesting and washing (Fig. 2C, D, Table 1). CD45+CD56− cells consisted mainly of CD14+ and/or CD15+ cells (Supplementary Table 1). CD3+ T cell content and CD19+ B cell content was < 1.0 × 105/kg and < 3.0 × 105/kg, respectively (Table 1). Maturation of the NK cell product was established with mean ± SD expression for CD16 8% ± 5, NKG2A 75% ± 11, NKG2D 63% ± 25, KIRs 11% ± 4, DNAM-1 85% ± 8, perforin 79% ± 10, NKp46 87% ± 8, NKp44 71% ± 19 and NKp30 84% ± 11 (Fig. 2E, Table 1). Moreover, functional activity after K562 challenging resulted in a mean CD107a+ expression of 52.7% ± 5.1 and IFNγ+ of 8.6% ± 1.8, which was comparable to culture in 6-well plates (Fig. 2F and Suppl Fig. 1, mean ± SEM, versus 4.5 ± 0.9 and 0.1 ± 0.0 respectively for unstimulated CD56+perforin+ NK cells (mean ± SD). Finally, HSPC-NK cells were evaluated in glycolytic and mitochondrial stress tests and compared to PB-NK cells. The changes in ECAR and OCR were analyzed showing adequate glycolysis [HSPC-NK 1.4 ± 0.5 fold change (mean ± SEM, n = 3) vs PB-NK 0.8 ± 0.1 (n = 2)] glycolytic capacity (HSPC-NK 2.5 ± 0.5 fold change vs PB-NK 3.9 ± 0.9), and maximal respiration (HSPC-NK 2.4 ± 0.4 pmol/min/normalized unit vs PB-NK 3.3 ± 0.2) (Fig. 2G, H). All cultures were sterile according to Ph. Eur. 2.6.1 and had low (< 0.3 EU/ml) endotoxin burden according to Ph. Eur. 2.6.14.
Mass cytometry analysis was performed to compare the immunophenotype of HSPC-NK cells generated with the GMP-compliant SR1/IL15/IL12 manufacturing protocol and the ‘old’ Hep/IL15/IL2 culture process (Fig. 3). For this we compared the phenotype of NKp46+CD56+CD3− NK cells (Fig. 3A, B). To complement Boolean gating, we also used an unbiased analysis approach (t-distributed stochastic neighbor embedding (tSNE)) and FlowSOM, a visualization technique to analyze high-dimensional data using self-organizing maps. Both culture methods resulted in distinct phenotypes of the generated NKp46+CD56+CD3− NK cells as visualized by tSNE analysis (Fig. 3C). SR1/IL15/IL12 HSPC-NK cells were phenotypically more mature (increased KIR and perforin expression) and activated (increased CD69 and CD25 expression) compared to Hep/IL15/IL2 differentiated HSPC-NK cells (Fig. 3D). FlowSom analysis revealed five population clusters of which cluster 1 is significantly lower in SR1/IL15/IL12 HSPC-NK cells compared to Hep/IL15/IL2 differentiated HSPC-NK cells (Fig. 3E, F). This cluster 1 resembles an immature NK cell phenotype with high expression of CD56, CD94, NKG2A and NKp46, but low expression of perforin, GzmB, DNAM-1 and KIR. Other NK cell clusters identified were not significantly different between the two methods. Collectively, these data show that we established an improved GMP-compliant HSPC-NK cell generation process with potent proliferation, maturation and functional activity.
Discussion
Here, we report on the development of a GMP-compliant manufacturing process of a CD34+ HSPC-derived NK cell product, named RNK001 cells. Highly functional allogeneic NK cells are generated using our SR1/IL15/IL12 culture protocol and a clinically relevant dose and purity (≥ 1.0 × 109 CD56+ cells and ≥ 70% purity) could be achieved. Importantly, these NK cells exhibit a mature and functional phenotype, with high expression of activating receptors NKG2D, DNAM-1 and NCR, resulting in adequate degranulation, cytokine production and proliferation. The robustness of this culture protocol was confirmed and documented in an IMPD.
With this SR1/IL15/IL12 protocol, we generate large numbers of highly functional NK cells from CD34+ HSPCs derived from UCB units. While other HSPC sources (e.g. mobilized peripheral blood) could be used, UCB-derived HSPC generally result in higher NK cell yields that can be multiple folds greater (data not shown). Alternatively, HSPC-NK cells can be generated from human induced pluripotent stem cells (iPSCs) [32,33,34]. iPSC-derived NK cells derive from a clonal starting cell population resulting in an unlimited number of uniform mature NK cells. However, the strength of our product is the heterogeneity between the final NK cell products due to subtle differences in donors [21, 33, 34]. In addition, in our previous clinical trial in vivo HSPC-NK cell maturation was observed, indicated by the rapid acquisition of CD16 and KIR expression, while expression of most activating receptors was sustained [21, 25]. Importantly, no genetic mutation based on karyotyping was observed previously even after 42 days of culture [22].
Allogeneic NK cell immunotherapy in general is known to be a safe and well-tolerated adjuvant therapy for patients with AML or MDS-EB2 [3, 5,6,7,8,9, 21, 35]. Prognosis of this patient category remains poor due to high relapse rates which is correlated with persistent MRD prior to allo-SCT. Therefore, we designed a prospective phase I/IIa trial called ‘Infusion of ex vivo-generated allogeneic NK cells in combination with subcutaneous (sc) IL2 in patients with acute myeloid leukemia’ (NCT04347616) to study the safety and efficacy of RNK001 cells with and without IL2 administration. The primary objective of phase I of the study is to evaluate the safety and toxicity of the infusion of RNK001 cells, with and without sc IL2, following a non-myeloablative immunosuppressive conditioning regimen. The primary objective of phase IIa of the study is to evaluate the effect of this immunotherapy regimen on disease activity in patients with AML or MDS-EB2, determined at day +28 post infusion (Fig. 4A, C).
Patients with AML (de novo and secondary) or MDS-EB2, aged ≥ 18 years, who have stable or at least non-rapidly progressive disease, with or without disease controlling medication and ineligible for allo-SCT will be included. Patients can be newly diagnosed, untreated, or suffer from relapsed or refractory disease after treatment. The first phase of the study is designed as standard 3 + 3 dose escalating study, comprising twelve patients. The second phase of the study is designed as Simon’s optimal two-stage single arm study, comprising seventeen patients. Prior to RNK001 infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu, cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day, for 3 consecutive days) lymphodepleting chemotherapy. Then, patients will receive a single dose of 1.0–3.0 × 109 RNK001 cells. In phase I patients will receive RNK001 cells without sc IL2, with 3.0 × 106 units sc IL2 or with 6.0 × 106 units sc IL2 (Fig. 4B). Patients will be screened for (serious) adverse events ((S)AEs) and GvHD, defining dose-limiting toxicities (DLTs). After establishing safety, phase IIa of the study will use the highest tolerable IL2 dose. Patients will be monitored for clinical toxicity, biological parameters in PB and BM and disease activity. Follow-up will last 6 months (Fig. 4C).
So far in other clinical studies up to 3.0 × 107/kg peripheral blood or UCB-derived allogeneic NK cells have been administered to relapsed or refractory AML patients [3, 5, 21]. Allogeneic NK cell infusions were well-tolerated without cytokine release syndrome (CRS) or GvHD. Subcutaneous IL2 administration up to 9.0 × 106 units was well-tolerated in earlier studies and IL2 side effects were dose related [3,4,5, 8, 36]. Common side effects include constitutional symptoms, hematologic toxicity and injection site reactions. Current therapies result in only 20% complete response in refractory or relapsed AML/MDS-EB2 patients. As allogeneic NK cell infusion has exerted promising anti-leukemia activity in the past, achieving up to 47% CR in poor prognosis AML patients with refractory or relapsed disease, our protocol could be a potential treatment option. This clinical trial protocol was approved by the Dutch Ethics Committee (Central Committee on Research Involving Human Subjects, CCMO) and the Competent Authority (Ministry of Health, Welfare and Sport, VWS) and is currently open for inclusion. The goal of our RNK001 platform in the future is (1) to induce deeper remissions before allo-SCT, (2) to boost the graft-versus-leukemia effect shortly after transplantation during the immunosuppressive window, (3) to treat an early relapse, or (4) as adjuvant therapy for allo-SCT ineligible patients.
Enhancing expansion and persistence of adoptive NK cell therapy will likely improve efficacy. In the previous PLMA25 study without exogenous cytokines, chimerism data showed transient HSPC-NK cell persistence in peripheral blood up to 21% until day 8 [21]. IL15 is crucial for NK cell survival, proliferation, and effector function. However, the first-in-human trials using systemic rhIL15 and IL15 super agonist complexes in patients treated with haploidentical NK cell therapy for advanced AML, showed expansion of host CD8+ T cells which resulted in CRS and rejection of allogeneic donor NK cells [10, 37]. Alternatively, multiple trials have combined NK cell administration with sc IL2 support, with limited described toxicity [3,4,5, 8, 9, 36]. Subcutaneous IL2 injections following high-dose chemotherapy and autologous SCT significantly expanded the number of circulating NK cells in vivo [38]. Miller and colleagues showed that there is a correlation between in vivo NK cell persistence and expansion of ≥ 100 donor NK cells/µl blood at day 7–14 after infusion in combination with in vivo IL2 boosting and achievement of CR in relapsed/refractory AML patients [5]. Our RNK001 cells show expression of CD25, the high affinity IL-2R, which may be advantageous when using low dose IL2. In our study, RNK001 cells will be infused without IL2, with low dose IL2 (3.0 × 106 units/dose) or high dose IL2 (6.0 × 106 units/dose). Subsequently both toxicity and efficacy of these treatment regimens can be compared.
To broaden the applicability of NK cell immunotherapy further improvements to the RNK001 product can be warranted. Currently, personalized RNK001 products are produced in 5 weeks. Including lead times this may result in exclusion of patients due to disease progression or deteriorating condition. Therefore, ongoing pre-clinical development is focused on generating a cryopreserved off-the-shelf product. The limited need for HLA matching allows for great flexibility in donor choice which makes banking a variety of common haplotypes and pooling of cryopreserved RNK001 cells highly feasible. Having a bank of cryopreserved RNK001 products available will greatly reduce time to infusion, allow for multiple infusions and may greatly reduce production cost. Other important ongoing pre-clinical developments to the RNK001 product include genetic modifications to improve tumor specific targeting and in vivo persistence. Liu et al. administered CAR-transduced UCB-derived-NK cells in CD19-positive lymphoid tumor patients that received Cy/Flu followed by a single infusion of CAR-NK cells at escalating doses. The NK cells not only expressed anti-CD19 CAR, but also IL15. The infused CAR/IL15-NK cells expanded and persisted at low levels for at least 12 months [39]. No adverse events such as GvHD, CRS or neurotoxicity were seen and a majority of the patients responded. Our platform is attractive for genetic engineering as well. Promising targets for CAR-NK cell therapy in AML patients include CD123 or CLL1 (CLEC12A) in combination with IL15/IL15Rα to improve persistence and expansion locally.
Altogether, this study shows the development of a GMP-compliant IL15/IL12/SR1-based HSPC-NK cell platform to generate large numbers of highly active NK cells. This method was validated and is now actively used in ongoing clinical trials. Meanwhile, future developments aim at optimization of the RNK001 product using genetic engineering and off-the-shelf availability. This platform will broaden the application of NK cell immunotherapy for AML/MDS-EB2 and potentially other malignancies.
Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
References
Shallis RM et al (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70–87
Anthias C et al (2014) Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant 49(5):679–683
Bachanova V et al (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123(25):3855–3863
Curti A et al (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118(12):3273–3279
Miller JS et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051–3057
Rubnitz JE et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28(6):955–959
Berrien-Elliott MM et al (2020) Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discov 10(12):1854–1871
Romee R et al (2016) Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 8(357):357ra123
Bjorklund AT et al (2018) Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin Cancer Res 24(8):1834–1844
Berrien-Elliott MM et al (2022) Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood 139(8):1177–1183
McKenna DH Jr et al (2007) Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 47(3):520–528
Geller MA et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13(1):98–107
Denman CJ et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7(1):e30264
Ojo EO et al (2019) Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep 9(1):14916
Otegbeye F et al (2022) A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors. Transplant Cell Ther 28(5):250 e1-250 e8
Ciurea SO et al (2022) Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36(1):155–164
Parkhurst MR et al (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17(19):6287–6297
Veluchamy JP et al (2017) The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol 8:631
Damele L et al (2022) Cord blood-derived natural killer cell exploitation in immunotherapy protocols: more than a promise? Cancers (Basel) 14(18):4439
Cany J et al (2013) Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS ONE 8(6):e64384
Dolstra H et al (2017) Successful transfer of umbilical cord blood CD34(+) hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin Cancer Res 23(15):4107–4118
Spanholtz J et al (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 6(6):e20740
Spanholtz J et al (2010) High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS ONE 5(2):e9221
Roeven MW et al (2015) The aryl hydrocarbon receptor antagonist stemregenin1 improves in vitro generation of highly functional natural killer cells from CD34(+) hematopoietic stem and progenitor cells. Stem Cells Dev 24(24):2886–2898
Cany J et al (2015) Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology 4(7):e1017701
Hoogstad-van Evert JS et al (2017) Umbilical cord blood CD34(+) progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg(null) mice. Oncoimmunology 6(8):e1320630
Van der Meer JMR et al (2021) IL-15 superagonist N-803 improves IFNgamma production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells. Cancer Immunol Immunother 70(5):1305–1321
Kotecha N, Krutzik PO, Irish JM (2010) Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom 53:10–17
Zunder ER et al (2015) Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat Protoc 10(2):316–333
el Amir AD et al (2013) viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 31(6):545–552
Van Gassen S et al (2015) FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87(7):636–645
Euchner J et al (2021) Natural killer cells generated from human induced pluripotent stem cells mature to CD56(bright)CD16(+)NKp80(+/−)in-vitro and express KIR2DL2/DL3 and KIR3DL1. Front Immunol 12:640672
Goldenson BH, Hor P, Kaufman DS (2022) iPSC-derived natural killer cell therapies—expansion and targeting. Front Immunol 13:841107
Zhu H, Kaufman DS (2019) An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells. Methods Mol Biol 2048:107–119
Berrien-Elliott MM, Jacobs MT, Fehniger TA (2023) Allogeneic natural killer cell therapy. Blood 141(8):856–868
Curti A et al (2016) Larger size of donor alloreactive NK cell repertoire correlates with better response to NK Cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res 22(8):1914–1921
Cooley S et al (2019) First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv 3(13):1970–1980
Miller JS et al (1997) Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 3(1):34–44
Liu E et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545–553
Acknowledgements
This research is financed by the Dutch Cancer Society KWF, Project Number 10100 and 11564, Postbus 75508, 1070 AM Amsterdam, and NIH Grants R01CA205239, P50CA171963. We would like to thank the Radboudumc Technology Center Flow cytometry for expertise in design and performance of the different flow cytometry-based experiments and the Radboudumc Technology Center Clinical studies for assistance in the logistics of the clinical trial.
Funding
This work was supported by the Dutch Cancer Society KWF, grant numbers 10100 and 11564, and NIH grants R01CA205239, P50CA171963. Radboudumc is patent holder of the improved method for ex vivo expansion CD34+ HSPCs into NK cells using an aryl hydrocarbon receptor antagonist (PCT/EP2016/071660). The authors have no other relevant financial or non-financial interests to disclose.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by PKJDJ, PMMH, MMB-E, JMRM, CMM and LDJ. Supervision of experiments was performed by WH, JHJ, TAF and HD. GMP manufacturing protocol and data were designed and reviewed by PKJDJ, WH, ALG and HD. Clinical study trial design was performed by PMMH, MR, NPMS and HD. The first draft of the manuscript was written by PKJDJ and PMMH, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interest
This work was supported by the Dutch Cancer Society KWF, grant numbers 10100 and 11564, and NIH grants R01CA205239, P50CA171963. Radboudumc is patent holder of the improved method for ex vivo expansion CD34+ HSPCs into NK cells using an aryl hydrocarbon receptor antagonist (PCT/EP2016/071660). The authors have no other relevant financial or non-financial interests to disclose.
Ethics approval
Approval of the clinical trial was granted by the Competent Authority The Ministry of Health, Welfare and Sports in The Netherlands and by the Dutch Central Committee on Research Involving Human Subjects (CCMO, EudraCT 2019-001929-27). The study will be performed in line with the principles of the Declaration of Helsinki.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
de Jonge, P.K.J.D., van Hauten, P.M.M., Janssen, L.D. et al. Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia. Cancer Immunol Immunother 72, 3323–3335 (2023). https://doi.org/10.1007/s00262-023-03492-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-023-03492-6